Coeptis Therapeutics Holdings, Inc. (COEP)
Apr 24, 2026 - COEP merged into ZSQR
16.40
+0.19 (1.17%)
Inactive · Last trade price on Apr 24, 2026
COEP Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1.41 | 1.36 | - | - | - | 0.08 | |
Revenue Growth | 2148.85% | - | - | - | - | 143.81% |
Cost of Revenue | 0.18 | 0.18 | - | - | - | - |
Gross Profit | 1.23 | 1.18 | - | - | - | 0.08 |
Selling, General & Admin | 9.67 | 10.73 | 5.62 | 13.35 | 34.18 | 14.12 |
Research & Development | 1.43 | 1.28 | 2.33 | 6.67 | 0.02 | - |
Amortization of Goodwill & Intangibles | 1 | 1 | 1 | 1 | - | - |
Operating Expenses | 14.13 | 14.23 | 10.05 | 21.49 | 34.2 | 14.12 |
Operating Income | -12.9 | -13.04 | -10.05 | -21.49 | -34.2 | -14.05 |
Interest Expense | -0.58 | -0.64 | -0.46 | -0.11 | -0.22 | -0.19 |
Interest & Investment Income | 0.12 | 0.12 | 0.23 | - | - | - |
Other Non Operating Income (Expenses) | 0.41 | 1.11 | -0.36 | 0.33 | 0.01 | 0.79 |
EBT Excluding Unusual Items | -12.95 | -12.46 | -10.64 | -21.27 | -34.41 | -13.45 |
Gain (Loss) on Sale of Investments | -0.2 | -0.09 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0 |
Asset Writedown | - | - | -0.04 | - | - | - |
Other Unusual Items | 0.27 | 0.27 | -0.2 | - | -3.17 | - |
Pretax Income | -12.88 | -12.28 | -10.88 | -21.27 | -37.57 | -13.45 |
Earnings From Continuing Operations | -12.88 | -12.28 | -10.88 | -21.27 | -37.57 | -13.45 |
Minority Interest in Earnings | 0.4 | 0.36 | 0.2 | - | - | - |
Net Income | -12.48 | -11.92 | -10.68 | -21.27 | -37.57 | -13.45 |
Net Income to Common | -12.48 | -11.92 | -10.68 | -21.27 | -37.57 | -13.45 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 5 | 4 | 2 | 1 | 1 | 1 |
Shares Outstanding (Diluted) | 5 | 4 | 2 | 1 | 1 | 1 |
Shares Change | 121.23% | 120.03% | 49.84% | 79.70% | 30.98% | 79.11% |
EPS (Basic) | -2.51 | -2.81 | -5.55 | -16.56 | -52.57 | -24.64 |
EPS (Diluted) | -2.51 | -2.81 | -5.55 | -16.56 | -52.57 | -24.64 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -8 | -8.6 | -6.65 | -7.24 | -3.88 | -4.49 |
Free Cash Flow Per Share | -1.61 | -2.03 | -3.46 | -5.64 | -5.42 | -8.23 |
Gross Margin | 87.22% | 86.75% | - | - | - | 100.00% |
Operating Margin | -912.42% | -956.94% | - | - | - | -18727.91% |
Profit Margin | -882.43% | -874.29% | - | - | - | -17932.37% |
Free Cash Flow Margin | -565.49% | -631.16% | - | - | - | -5985.92% |
EBITDA | -11.72 | -11.86 | -9.05 | -20.49 | -33.19 | -13.6 |
D&A For EBITDA | 1.18 | 1.18 | 1 | 1 | 1 | 0.45 |
EBIT | -12.9 | -13.04 | -10.05 | -21.49 | -34.2 | -14.05 |
Revenue as Reported | 1.41 | 1.36 | - | - | - | 0.08 |